Dyne Therapeutics, Inc. (DYN)

NASDAQ: DYN · IEX Real-Time Price · USD
11.90
-0.03 (-0.25%)
Dec 2, 2022 4:00 PM EST - Market closed
-0.25%
Market Cap 621.87M
Revenue (ttm) n/a
Net Income (ttm) -181.06M
Shares Out 51.80M
EPS (ttm) -3.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 166,058
Open 11.87
Previous Close 11.93
Day's Range 11.52 - 12.18
52-Week Range 4.3 - 15.63
Beta 0.05
Analysts Buy
Price Target 25.50 (+114.3%)
Earnings Date Nov 3, 2022

About DYN

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.. [Read more]

Industry Independent Power and Renewable Electricity Producers
IPO Date Sep 17, 2020
Employees 115
Stock Exchange NASDAQ
Ticker Symbol DYN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for DYN stock is "Buy." The 12-month stock price forecast is 25.5, which is an increase of 114.29% from the latest price.

Price Target
$25.5
(114.29% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Wall Street Analysts Predict a 141% Upside in Dyne Therapeutics, Inc. (DYN): Here's What You Should Know

The mean of analysts' price targets for Dyne Therapeutics, Inc. (DYN) points to a 141% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am...

3 days ago - Zacks Investment Research

Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

- DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Underway with Data Anticipated in the Second Half of 2023 -

1 month ago - GlobeNewsWire

Dyne Therapeutics to Present at Investor Conferences in November

WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people...

1 month ago - GlobeNewsWire

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

- Company Anticipates Reporting Data from Global, Multiple Ascending Dose DELIVER Clinical Trial in the Second Half of 2023 -

1 month ago - GlobeNewsWire

Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 a...

- Poster Highlights In Vivo Data for DYNE-251, Now Being Evaluated in Phase 1/2 DELIVER Clinical Trial in Patients Amenable to Exon 51 Skipping - - First Presentation of In Vitro Data for FORCE™  Platfo...

1 month ago - GlobeNewsWire

Dyne Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference

WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peopl...

2 months ago - GlobeNewsWire

Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During “Spotlight on the Clinic” Virtual Event

- Presentation and Discussion with Two Leading Neuromuscular Disease Experts -

2 months ago - GlobeNewsWire

Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peopl...

2 months ago - GlobeNewsWire

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic ...

- First Patient Expected to be Dosed in September -

2 months ago - GlobeNewsWire

Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of ...

- Data from Global, Multiple Ascending Dose DELIVER Trial Anticipated in the Second Half of 2023 -

2 months ago - GlobeNewsWire

Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development

- Appointment Expands Dyne's Development Team as Company Advances Multiple Programs into Clinical Trials -

3 months ago - GlobeNewsWire

Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic...

- FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx Model -

3 months ago - GlobeNewsWire

Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 -

3 months ago - GlobeNewsWire

Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories"

Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ: RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ: DYN) with a Buy rating and a price target of $...

Other symbols: RNA
4 months ago - Benzinga

Best Momentum Stocks to Buy for July 18th

DINO, DYN, and DLNG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 18, 2022.

Other symbols: DINODLNG
4 months ago - Zacks Investment Research

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystro...

- Initiation of Dosing in Multiple Ascending Dose Clinical Trial of DYNE-101 in Patients with DM1 On Track for Mid-2022 -

4 months ago - GlobeNewsWire

What's Going On With Dyne Therapeutics Shares Today?

Dyne Therapeutics Inc (NASDAQ: DYN) shares are trading lower by 5.42% to $6.81 after the company announced FDA clearance of its Investigational New Drug application for DYNE-251 for the treatment of Duc...

4 months ago - Benzinga

Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dyst...

- Initiation of Dosing in Multiple Ascending Dose Clinical Trial in Patients with Mutations Amenable to Skipping Exon 51 On Track for Mid-2022 -

4 months ago - GlobeNewsWire

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

WALTHAM, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with ge...

6 months ago - GlobeNewsWire

Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Le...

- Initiation of Dosing in Multiple Ascending Dose Clinical Trial for DYNE-101 in Patients with Myotonic Dystrophy Type 1 Anticipated in Mid-2022 -

6 months ago - GlobeNewsWire

Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Anticipated in Mid-2022 -

7 months ago - GlobeNewsWire

selfologi Chooses Digital Technology Consulting Partner Grid Dynamics to Launch Its Cosmetic Treatment Platform

SAN RAMON, CA / ACCESSWIRE / March 17, 2022 / Grid Dynamics Holdings, Inc. (NASDAQ:DYN) (Grid Dynamics), a leader in enterprise-level digital engineering services and solutions, today announced it has l...

8 months ago - Accesswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

- Response to FDA for DYNE-251 IND in DMD on Track for Submission in the Second Quarter of 2022 - - Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-1...

8 months ago - GlobeNewsWire

Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors

WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with g...

9 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

New York, New York--(Newsfile Corp. - February 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors ...

10 months ago - Newsfile Corp